Patents Examined by Patrick Twomey
  • Patent number: 5840707
    Abstract: The instant disclosure relates to cochleates comprising a) a biologically relevant molecule component b) a negatively charged lipid component, and c) a divalent cation component. The cochleate has an extended shelf life, even in a desiccated state. Advantageously, the cochleate can be ingested. The biologically relevant molecule can be a polynucleotide.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: November 24, 1998
    Assignees: Albany Medical College, University of Medicine and Dentistry of New Jersey
    Inventors: Raphael James Mannino, Susan Gould-Fogerite
  • Patent number: 5767099
    Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.
    Type: Grant
    Filed: October 20, 1995
    Date of Patent: June 16, 1998
    Assignee: Genzyme Corporation
    Inventors: David J. Harris, Edward R. Lee, Craig S. Siegel, Eric A. Rowe, Shirley C. Hubbard
  • Patent number: 5747325
    Abstract: The present disclosure relates to the application of genetic engineering to provide artificial .beta. cells, i.e. cells which can secrete insulin in response to glucose. This is achieved preferably through the introduction of one or more genes selected from the insulin gene, glucokinase gene, and glucose transporter gene, so as to provide an engineered cell having all three of these genes in a biologically functional and responsive configuration. Assays for detecting the presence of diabetes-associated antibodies in biological samples using these and other engineered cells expressing diabetes-associated epitopes are described. Also disclosed are methods for the large-scale production of insulin by perfusing artificial .beta. cells, grown in liquid culture, with glucose-containing buffers.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: May 5, 1998
    Assignee: Board of Regents, The University of Texas System
    Inventor: Christopher B. Newgard
  • Patent number: 5747471
    Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from ether or ester-linked alkyl groups, and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.
    Type: Grant
    Filed: October 11, 1995
    Date of Patent: May 5, 1998
    Assignee: Genzyme Corporation
    Inventors: Craig S. Siegel, David J. Harris, Edward R. Lee, Shirley C. Hubbard, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule, Mathieu B. Lane, Eric A. Rowe
  • Patent number: 5656611
    Abstract: The invention provides compositions for stabilizing polynucleic acids and increasing the ability of polynucleic acids to cross cell membranes and act in the interior of a cell. In one aspect, the invention provides a polynucleotide complex between a polynucleotide and certain polyether block copolymers. Preferably the polynucleotide complex will further include a polycationic polymer. In another aspect, the invention provides a polynucleotide complex between a polynucleotide and a block copolymer comprising a polyether block and a polycation block. In yet another aspect, the invention provides polynucleotides that have been covalently modified at their 5' or 3' end to attach a polyether polymer segment. In still another aspect, the invention provides certain preferred polycationic polymers.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: August 12, 1997
    Assignee: Supratek Pharma Inc.
    Inventors: Alexander Victorovich Kabanov, Valery Yulievich Alakhov, Sergey V. Vinogradov
  • Patent number: 5635487
    Abstract: The present invention provides a composition comprising a population of micelles wherein each micelle comprises at least one amphipathic compound layer that surrounds a non-aqueous core that contains a polyion. Also provided are a method of preparing such a composition and the uses of such compositions for delivering biologically active polyions to cells.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: June 3, 1997
    Inventors: Jon A. Wolff, Vladimir Budker, Vladimir Gurevich